H.C. Wainwright initiated coverage of Jade Biosciences Inc. with a Buy rating and a $25 price target on January 7. The firm stated the company is strategically positioned to secure a leadership role within the autoimmune market.
Jade Biosciences highlighted major progress for its lead candidate, JADE101, in the third quarter of 2025. The company also introduced a new development program called JADE201.
A $135 million private placement was completed in October, extending the company's cash runway into the first half of 2028. This positions Jade to hit several upcoming clinical milestones.
JADE101 is a selective anti-APRIL monoclonal antibody designed for patients with immunoglobulin A nephropathy. Preclinical data showed the drug was well-tolerated in non-human primates, establishing a no-observed-adverse-effect level that supports its current Phase 1 trial.
The drug demonstrated reversible reductions in serum immunoglobulins without broad immune suppression. H.C. Wainwright projects JADE101 could generate $926 million in risk-adjusted revenue by 2037.
Jade Biosciences Inc. operates as a biotech company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.